EGFR and lung cancer: For example, the covalent mutant-selective EGFR inhibitor osimertinib showed striking therapeutic effects in EGFR-mutated lung cancer, which were less pronounced with reversible, first-generation EGFR inhibitors such as gefitinib and erlotinib46.